Not otherwise specified 3-MGA-uria type
Alternate names[edit]
3 alpha methylglutaconic aciduria type IV; 3 methylglutaconic aciduria type IV
Definition[edit]
3-methylglutaconic aciduria (3-MGA) type IV, or unclassified 3-MGA, is a clinically heterogeneous disorder characterised by increased 3-methylglutaconic acid excretion in individuals that cannot be classified as having one of the other forms of 3-MGA (3-MGA I, II or III).
Epidemiology[edit]
The prevalence of this disorder is unknown.
Cause[edit]
The cause remains unknown, unlike patients with 3-MGA type I, individuals with 3MGA type IV display normal 3-methylglutaconyl-CoA hydratase activity in cultured fibroblasts. Mitochondrial respiratory chain abnormalities have been detected in some 3MGA type IV patients but the clinical heterogeneity associated with this disorder suggests that the 3-methylglutaconic aciduria seen in 3-MGA type IV patients may result from a variety of causes and genetic factors.
Inheritance[edit]

The disorder has been reported to be inherited as an autosomal recessive trait.
Signs and symptoms[edit]
- Patients usually present during the first year of life with neurological findings including psychomotor retardation, hypotonia, developmental delay, seizures and progressive spasticity, together with severe failure to thrive.
- Cardiomyopathy, hepatic dysfunction, eye anomalies, microcephaly, deafness, dysmorphism, neonatal hypoglycaemia, thrombocytopaenia and lactic acidosis have also been reported.
- Cerebellar dysgenesis may be revealed by magnetic resonance imaging. In contrast, a small number of asymptomatic patients have been diagnosed as having 3-MGA type IV.
For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms
- 3-Methylglutaconic aciduria
- Failure to thrive(Faltering weight)
- Global developmental delay
- Intellectual disability(Mental deficiency)
- Muscular hypotonia(Low or weak muscle tone)
- Seizure
- Spasticity(Involuntary muscle stiffness, contraction, or spasm)
30%-79% of people have these symptoms
- Dysgenesis of the cerebellar vermis
5%-29% of people have these symptoms
- Cardiomyopathy(Disease of the heart muscle)
- Cataract(Clouding of the lens of the eye)
- Decreased liver function(Liver dysfunction)
- Hearing impairment(Deafness)
- Hypoglycemia(Low blood sugar)
- Iris [[hypopigmentation](Light eye color)
- Lactic acidosis(Increased lactate in body)
- Microcephaly(Abnormally small skull)
- Thrombocytopenia(Low platelet count)
Diagnosis[edit]
3-methylglutaconic aciduria can be diagnosed by analysis of urinary organic acid excretion but specific diagnosis of 3-MGA type IV requires exclusion of all other forms of 3-MGA. As the genetic factors responsible for the other forms of 3-MGA have now been determined, molecular analysis provides a valuable tool for accurate diagnosis.
Treatment[edit]
At present there is no effective treatment for 3-MGA type IV and a leucine-restricted diet appears to be of no benefit.
Prognosis[edit]
The prognosis depends on the clinical phenotype but the neurological complications can be severe with a potentially fatal disease course.
NIH genetic and rare disease info[edit]
Not otherwise specified 3-MGA-uria type is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Not otherwise specified 3-MGA-uria type
|
|
This article is a stub You can help WikiMD by registering and expanding it with useful details, internal links, formatting, and categories. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health and wellness encyclopedia. |
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian